Evaluation of an Exercise Intervention for Vincristine Induced Peripheral Neuropathy in Pediatric Cancer Patients (Exercise)
Primary Purpose
Peripheral Neuropathy
Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Exercise
Sponsored by
About this trial
This is an interventional treatment trial for Peripheral Neuropathy
Eligibility Criteria
Inclusion Criteria:
Participants will be eligible for this study if they are:
- age ≥ 5 and ≤ 18 years,
- have been diagnosed with acute lymphoblastic leukemia (ALL),
- will undergo the standard of care treatment for ALL with vincristine.
- will have a TNS-PV score of >3 at week 6
Exclusion Criteria:
Participants will be ineligible for this study if they have:
- baseline peripheral neuropathy greater than grade 1 (prior to receiving any doses of vincristine),
- evidence of significant liver dysfunction,
- Down's Syndrome,
- pregnancy,
- severe illness or infection,
- current active treatment with erythropoietin,
- administration of vitamin supplements above 100% of the recommended daily allowance
Sites / Locations
- Riley Hospital for Children - Indiana University
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Exercise Intervention
Arm Description
Clinic and at home exercise sessions.
Outcomes
Primary Outcome Measures
Number of Participants With Greater Than 50% Compliance to Exercise Regimen
Subjects will complete greater than 50% of exercise sessions during 8 week intervention. Subject report satisfaction with the intervention via questionnaires.
Acceptability - Parent Satisfaction Survey
Parents will also be asked to complete a satisfaction survey regarding the exercise program, DVDs, and therapist support. The satisfaction survey consists of 13 items. Scores were on a Likert scale 1-5, 1 - strongly disagree and 5 - strongly agree. The total range is 13-65 with 65 being the greatest satisfaction possible and 13 being the worst satisfaction possible.
Secondary Outcome Measures
Acceptability - Patient Satisfaction Survey
Patients will provide feedback on the exercise program, DVDs, and therapist support. The satisfaction survey consists of 13 items. The scale is 1-5 with 1 - strongly disagree and 5 - strongly agree. The total range is 13-65 with 65 being the greatest satisfaction possible and 13 being the worst satisfaction possible.
Pediatric Neuropathy
Total Neuropathy Score Pediatric Version; Range for each subscale is 0 to 4 with 0 being normal and 4 being the worst neuropathy. The total range is 0-36. 0 being no neuropathy. 36 being highest neuropathy possible.
Quality of Life - Changes in Quality of Life From Pre Intervention to Post Intervention a Total of 8 Weeks.
Quality of Life: Pediatric Quality of Life Inventory; Each is 0 to 4 with 0 being never and 4 being almost always. The total scale score, the mean is computed as the sum of all the items over the number of items answered on all the scales. The difference between pre and post QOL scores. Total scale score consists of 4 dimensions, physical, emotional, social, and school functioning. Scores are transformed on a scale from 0-100. The greater the score the better the quality of life.
PDGF-BB Levels (Platelet Derived Growth Factor)
Changes in PDGF-BB (Platelet Derived Growth Factor) levels in plasma from pre to post intervention.
NGF (Nerve Growth Factor)
Change in NGF (Nerve Growth Factor) in plasma from pre to post intervention.
Quality of Life as a Result in Changes in Neuropathy Scores.
Analyzing the correlation of changes in quality of life scores with neuropathy scores using Pearson's correlation coefficient.
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT03430674
Brief Title
Evaluation of an Exercise Intervention for Vincristine Induced Peripheral Neuropathy in Pediatric Cancer Patients
Acronym
Exercise
Official Title
Evaluation of an Exercise Intervention for Vincristine Induced Peripheral Neuropathy in Pediatric Cancer Patients
Study Type
Interventional
2. Study Status
Record Verification Date
March 2023
Overall Recruitment Status
Completed
Study Start Date
July 1, 2018 (Actual)
Primary Completion Date
October 30, 2019 (Actual)
Study Completion Date
October 30, 2019 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Indiana University
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The purpose of this study is to better understand whether or not children with ALL can complete an exercise program during treatment and whether or not that program may impact peripheral neuropathy. Researchers will also study changes in the blood and body that may occur during the program by collecting samples of blood at various times during the study.
Aim 1: Evaluate the feasibility and acceptability of EX as an intervention for VIPN in pediatric patients with ALL.
Aim 2: Estimate preliminary effect sizes of the EX intervention.
Detailed Description
Baseline visit (week 6):
This visit may take up to 1.5 hours total.
The subject's exercise therapist will meet with them to discuss what they can expect throughout the program period. The subject will receive their exercise DVD to be used for at-home exercise sessions.
The subject will be asked questions about how they are feeling and their general well-being. The subject will also be asked to complete several questionnaires about their neuropathy, confidence level about completing the program, support and expectations.
The subject will be given a Fitbit with instructions about how and when to use it.
The subject will have a sample of blood collected (15mL or about 1 tablespoon). The study team will time this blood draw to occur when they are already having blood drawn for routine clinical treatment.
The subject will have a physical fitness test, which includes body measurements such as weight, height and blood pressure; also tests for physical strength, endurance and oxygen consumption. At the same time the subject is given the physical fitness test they will also be asked to not eat for 1 hour before this session.
The subject will complete their first exercise session with their therapist.
Weeks 6-13:
During weeks 6-13 (8 weeks total), the subject will be asked to exercise for at least 15 minutes 6 times per week using the instructional DVD that was provided to them. The exercise the subject does will be tailored to their age range (either age 5-10 or 11-18) and will consist of strengthening and aerobic activities. The subject will also be asked to keep an exercise log that is provided by the study to record their exercise activity including how they felt when they exercised. The subject will be asked to perform one of their exercise sessions during weeks 8, 10, and 12 at Riley Hospital with their exercise therapist. The study team will coordinate this visit to occur during one of their regularly scheduled office visits. Post-program visit (week 14) This visit may take up to 1.5 hours total.
The subject will be asked questions about how they are feeling and their general well-being. The subject will also be asked to complete several questionnaires about your neuropathy, confidence level about completing the program, support and expectations.
The subject will have a sample of blood collected (15mL or about 1 tablespoon). The study team will time this blood draw to occur when they are already having blood drawn for routine clinical treatment.
The subject will repeat the physical fitness test, which includes body measurements such as weight, height and blood pressure; also tests for physical strength, endurance and oxygen consumption. During the last session (week 14) the subject will also be asked to not eat for 1 hour before this session.
The subject will be asked to complete a satisfaction survey.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Peripheral Neuropathy
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
10 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Exercise Intervention
Arm Type
Experimental
Arm Description
Clinic and at home exercise sessions.
Intervention Type
Behavioral
Intervention Name(s)
Exercise
Intervention Description
Exercise, questionnaires and blood draws.
Primary Outcome Measure Information:
Title
Number of Participants With Greater Than 50% Compliance to Exercise Regimen
Description
Subjects will complete greater than 50% of exercise sessions during 8 week intervention. Subject report satisfaction with the intervention via questionnaires.
Time Frame
8 weeks
Title
Acceptability - Parent Satisfaction Survey
Description
Parents will also be asked to complete a satisfaction survey regarding the exercise program, DVDs, and therapist support. The satisfaction survey consists of 13 items. Scores were on a Likert scale 1-5, 1 - strongly disagree and 5 - strongly agree. The total range is 13-65 with 65 being the greatest satisfaction possible and 13 being the worst satisfaction possible.
Time Frame
8 weeks
Secondary Outcome Measure Information:
Title
Acceptability - Patient Satisfaction Survey
Description
Patients will provide feedback on the exercise program, DVDs, and therapist support. The satisfaction survey consists of 13 items. The scale is 1-5 with 1 - strongly disagree and 5 - strongly agree. The total range is 13-65 with 65 being the greatest satisfaction possible and 13 being the worst satisfaction possible.
Time Frame
8 weeks
Title
Pediatric Neuropathy
Description
Total Neuropathy Score Pediatric Version; Range for each subscale is 0 to 4 with 0 being normal and 4 being the worst neuropathy. The total range is 0-36. 0 being no neuropathy. 36 being highest neuropathy possible.
Time Frame
8 weeks
Title
Quality of Life - Changes in Quality of Life From Pre Intervention to Post Intervention a Total of 8 Weeks.
Description
Quality of Life: Pediatric Quality of Life Inventory; Each is 0 to 4 with 0 being never and 4 being almost always. The total scale score, the mean is computed as the sum of all the items over the number of items answered on all the scales. The difference between pre and post QOL scores. Total scale score consists of 4 dimensions, physical, emotional, social, and school functioning. Scores are transformed on a scale from 0-100. The greater the score the better the quality of life.
Time Frame
Baseline and 8 weeks
Title
PDGF-BB Levels (Platelet Derived Growth Factor)
Description
Changes in PDGF-BB (Platelet Derived Growth Factor) levels in plasma from pre to post intervention.
Time Frame
Baseline (T1=week 6) and T2=week 14
Title
NGF (Nerve Growth Factor)
Description
Change in NGF (Nerve Growth Factor) in plasma from pre to post intervention.
Time Frame
Baseline (T1=week 6) and T2=week 14
Title
Quality of Life as a Result in Changes in Neuropathy Scores.
Description
Analyzing the correlation of changes in quality of life scores with neuropathy scores using Pearson's correlation coefficient.
Time Frame
8 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
5 Years
Maximum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Participants will be eligible for this study if they are:
age ≥ 5 and ≤ 18 years,
have been diagnosed with acute lymphoblastic leukemia (ALL),
will undergo the standard of care treatment for ALL with vincristine.
will have a TNS-PV score of >3 at week 6
Exclusion Criteria:
Participants will be ineligible for this study if they have:
baseline peripheral neuropathy greater than grade 1 (prior to receiving any doses of vincristine),
evidence of significant liver dysfunction,
Down's Syndrome,
pregnancy,
severe illness or infection,
current active treatment with erythropoietin,
administration of vitamin supplements above 100% of the recommended daily allowance
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jamie Renbarger, MD
Organizational Affiliation
Riley Hospital for Children - Indiana University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Riley Hospital for Children - Indiana University
City
Indianapolis
State/Province
Indiana
ZIP/Postal Code
46202
Country
United States
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Evaluation of an Exercise Intervention for Vincristine Induced Peripheral Neuropathy in Pediatric Cancer Patients
We'll reach out to this number within 24 hrs